Eli Lil­ly ush­ers up-and-com­ing GIP/GLP-1 drug in­to PhI­II as No­vo Nordisk ri­val wows with im­pres­sive re­sults

With No­vo Nordisk’s GLP-1 drug Ozem­pic (semaglu­tide) on its tail, Eli Lil­ly has round­ed up some mid-stage da­ta to show it has the right can­di­date to fol­low on Trulic­i­ty’s block­buster suc­cess in the com­pet­i­tive di­a­betes mar­ket.

In­ves­ti­ga­tors re­port that LY3298176, a dual GIP and GLP-1 re­cep­tor ag­o­nist, out­per­formed both place­bo and Trulic­i­ty (du­laglu­tide) in terms of blood sug­ar re­duc­tion and weight loss for pat­ints with type 2 di­a­betes. And while cross-tri­al com­par­isons al­ways war­rant cau­tion, the drug ap­pears to of­fer a siz­able ad­di­tion­al ef­fect over GLP monother­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER